ARTICLE | Company News
Micrologix, Virogen deal
February 9, 2004 8:00 AM UTC
MBI acquired global rights to Virogen's celgosivir, an oral antiviral in Phase I/II testing to treat chronic HCV. MBI plans to start Phase II testing this year. Virogen will receive an upfront payment...